He noted that the antiviral drug favipiravir is included in the temporary methodological recommendations "Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)", approved by the Russian Ministry of Health.
"In the near future, favipiravir will be included in the list of vital essential drugs (VED), after which the maximum prices for the drug will be registered in accordance with the approved methodology, which includes an economic analysis by the antimonopoly service," RIA Novosti quoted Kuznetsova as saying.
Earlier it was reported that the recommended cost of the drug "Areplivir" (favipiravir) for the treatment of a new coronavirus infection is 12 320 rubles.